RxDoctor Payments Data

Jazmine Weldy

Family · South Bend, INNPI 1912527474

Payments from drug & device makers

$2,727in general payments, 2019–2025

Across 137 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$708
  • Boston Scientific$227
  • Medtronic$188
  • Merck$185
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$179
  • Johnson & Johnson$143
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,727 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$14,496
Medicare patients
141
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$277,091
XareltoRivaroxaban71$97,573
EntrestoSacubitril/Valsartan35$46,507
BrilintaTicagrelor53$24,491
Repatha SureclickEvolocumab15$12,505
Dofetilide73$12,466
Propafenone Hcl ErPropafenone Hcl14$2,467
Metoprolol Succinate233$2,330
Flecainide Acetate35$1,651
Amiodarone Hcl58$1,163
Atorvastatin Calcium155$848
Potassium Chloride60$813
Isosorbide Mononitrate ErIsosorbide Mononitrate104$775
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$703
Propafenone Hcl13$627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$277,091254 claims
Johnson & JohnsonXarelto$143$97,57371 claims
NovartisEntresto$708$46,50735 claims
AstraZenecaBrilinta$30$24,49153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.

Other family in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →